Novotech (Australia) Pty Ltd
Vaccine - altered antigen expression; Vaccine – pathogenicity attenuation, replication incompetent
This licence allows Clinical Network Services (CNS) to run a clinical trial using a GM influenza vaccine. The test vaccine will be imported and will be tested on up to 240 consenting volunteers in clinical facilities in Perth, Adelaide, Melbourne, Sydney or Brisbane. The vaccine will be given by spraying it into the noses of the volunteers. The trial could run for up to three years. Clinical trials in Australia are also overseen by the Therapeutic Goods Administration (TGA) and so Novotech will also need approval from TGA before the trial can start.
Clinical trials in Australia must also follow the National Statement on Ethical Conduct in Human Research and the Guidelines for Good Clinical Practice of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Novotech will also need permission from the Department of Agriculture, Water and the Environment to import the GM vaccine.
The risk analysis for this application was carried out in accordance with the Regulator’s Risk Analysis Framework.
Outlines the Regulator’s decision to issue a licence following the assessment of this application.
FAQs on the licence application and the Regulator’s decision to issue a licence for this application.
A summary of the Risk Assessment and Risk Management Plan prepared as part of the assessment of this application. It provides a brief description of the licence application, the risk assessment and risk management plan.
The final risk assessment and management plan prepared to support the Regulator's decision. It describes the GMO(s) and proposed work with the GMO(s) and provides an assessment of potential risks posed by the GMO(s). It also includes a summary of submissions received during the public consultation process.